---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-126640"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2022-12-13T23:59:59+00:00"
generated_at: "2026-06-21T05:23:43.718852+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Aclaris Therapeutics enters separation agreement with retiring executive Frank Ruffo

## Summary
- Frank Ruffo's retirement separation agreement approved; includes consulting deal through March 2, 2023 for $25,000.
- Ruffo will continue vesting of outstanding options and RSUs during the consulting period.
- Exercise period for vested options extended to December 31, 2023.
- Ruffo retains eligibility for 2022 annual bonus and accrued pay/vacation.

## SEC filing metadata
- accession: 0001104659-22-126640
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2022-12-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000110465922126640/0001104659-22-126640-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000110465922126640/tm2232516d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-126640
- JSON: https://secwatch.observer/filing/0001104659-22-126640.json
- Plain text: https://secwatch.observer/filing/0001104659-22-126640.txt

## Key facts
- Executive change
  Frank Ruffo retired as other_named_officer at Aclaris Therapeutics, Inc..
  - Action: retired
  source text: In connection with Mr. Ruffo’s previously announced retirement, on December 9, 2022, Aclaris Therapeutics, Inc. (the “ Company ”) and Mr. Ruffo entered into a Separation Agreement and General Release
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000110465922126640/0001104659-22-126640-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.